Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results and Pipeline Review on March 2, 2021

Rhea-AI Summary

Eagle Pharmaceuticals (EGRX) will announce its Q4 and full-year 2020 financial results on March 2, 2021, before market opening. The event will feature a 90-minute conference call hosted by CEO Scott Tarriff and CFO Brian Cahill, starting at 8:30 a.m. ET. Investors can participate by calling toll-free or internationally. A replay will be available for a week post-call. Eagle focuses on developing innovative treatments, including RYANODEX®, BENDEKA®, and BELRAPZO®, aiming to address unmet medical needs across various conditions.

Positive

• Eagle Pharmaceuticals is fully integrated with R&D, clinical, manufacturing, and commercial expertise.
• The company has a diversified product pipeline including RYANODEX®, BENDEKA®, and BELRAPZO®.

Negative

• None.

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 fourth quarter and full year financial results on Tuesday, March 2, 2021, before the market opens.

Scott Tarriff, Chief Executive Officer, Brian Cahill, Chief Financial Officer, senior members of Eagle’s executive leadership team, and other distinguished external speakers will host a 90- minute conference call as follows:

Date	Tuesday, March 2, 2021
Time	8:30 a.m. ET
Toll free (U.S.)	877-876-9173
International	785-424-1667
Webcast (live and replay)	www.eagleus.com, under the “Investor Relations” section

A replay of the conference call will be available for one week after the call's completion by dialing 800-934-7612 (US) or 402-220-6980 (International) and entering conference call ID EGRXQ420. The webcast will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include RYANODEX^®, BENDEKA^®, BELRAPZO^®, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005837/en/

FAQ

When will Eagle Pharmaceuticals release its Q4 2020 financial results?

Eagle Pharmaceuticals will release its Q4 2020 financial results on March 2, 2021, before the market opens.

What time is the Eagle Pharmaceuticals conference call on March 2, 2021?

The conference call will begin at 8:30 a.m. ET on March 2, 2021.

How can I listen to the Eagle Pharmaceuticals financial results conference call?

You can listen to the conference call by dialing 877-876-9173 (U.S.) or 785-424-1667 (International).

What products does Eagle Pharmaceuticals offer?

Eagle Pharmaceuticals offers products such as RYANODEX®, BENDEKA®, and BELRAPZO®.

Is there a replay available for the Eagle Pharmaceuticals conference call?

Yes, a replay of the conference call will be available for one week after the call's completion.